dMed-Clinipace Announces Completion of US$50 Million Series C+ Financing From New Investors
dMed-Clinipace, the global full-service Clinical Contract Research Organization (CRO), announced the successful completion of a US$50 million Series C+ financing with participation from a group of new, leading international healthcare investors. Led by Springhill Fund, the round also saw contributions from funds managed by Rock Springs Capital and Superstring Capital.
dMed-Clinipace’s Global Chairman and CEO, Dr. Lingshi Tan, said, “We are delighted to welcome this new group of leading specialist investors, who will bring tremendous resources and strategic insight to accelerate our global growth while also further expanding our investor base. We are also grateful to existing investors who have kindly supported in every way to make this Series C+ possible and helped set up a strong foundation for our global progress.”
UF startup Clinipace merged with dMed Global to meet the needs of fast-moving biotech, pharma and medical device companies, and accelerate the delivery of innovative solutions to patients worldwide.
Learn more about dMed-Clinipace Announces Completion of US$50 Million Series C+ Financing From New Investors.